London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year

CEO Sander van Deventer describes the science behind delivering antibodies this way, and learnings he has taken away from the gene therapy field. Plus, the investments in manufacturing the company has already been making.